Skip to main content

A Phase 3 Trial of a JAKi in Patients With Giant Cell Arteritis Sponsored by AbbVie Medical Affairs + Health Impact

Listen as coinvestigator and rheumatologist Dr. Andrea Rubbert-Roth reviews this Phase 3 trial of a JAKi in patients with giant cell arteritis. Dr. Rubbert-Roth discusses the latest results, including efficacy and safety outcomes.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

×